We are live on ! Find out more
VYGR icon

Voyager Therapeutics

78 hedge funds and large institutions have $96.8M invested in Voyager Therapeutics in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 20 increasing their positions, 28 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

4% less call options, than puts

Call options by funds: $718K | Put options by funds: $747K

9.55% less ownership

Funds ownership: 71.68%62.14% (-9.5%)

23% less funds holding

Funds holding: 10178 (-23)

25% less capital invested

Capital invested by funds: $130M → $96.8M (-$33M)

29% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 28

59% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 39

Holders
78
Holders Change
-23
Holders Change %
-22.77%
% of All Funds
1.36%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
16
Increased
20
Reduced
28
Closed
39
Calls
$718K
Puts
$747K
Net Calls
-$29K
Net Calls Change
+$1.29M

VYGR Hedge Fund Activity: Q2 2021 in Review

78 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q2 2021, worth a combined $96.8M — down 25% from $130M a quarter earlier.

Sellers outnumbered buyers: 39 funds closed out of VYGR and 16 opened new positions — a net loss of 23 holders — while 28 trimmed existing stakes and 20 added.

The largest buyer was Citadel Advisors, adding an estimated $6.18M. The largest seller was BlackRock, cutting an estimated $7.16M.

  • 78 institutional investors held Voyager Therapeutics (VYGR) as of Q2 2021, down from 101 in Q1 2021.
  • Funds reported $96.8M of Voyager Therapeutics stock for Q2 2021, down 25% quarter-over-quarter.
  • 16 funds opened new Voyager Therapeutics positions in Q2 2021 and 39 closed out, a net change of -23 holders.
  • The largest Voyager Therapeutics buyer in Q2 2021 was Citadel Advisors, an estimated $6.18M added.
  • The largest Voyager Therapeutics seller in Q2 2021 was BlackRock, an estimated $7.16M sold.

Based on aggregated 13F filings for Q2 2021.